National Institute on Drug Abuse (NIDA)

• Notice of Special Interest- NOT-DA-21-007: Using Data to Advance HIV Epidemic Knowledge and Program Planning...

Read more about NIDA, NIMH, NIDCD Funding Opportunity Announcements

Dr. James Billingsley shared a presentation recently to highlight the Bioinformatics support available through the HU CFAR Biostatistics and Bioinformatics Core.  Did you know Harvard affiliated HIV researchers can access free grant support, Exp. design, power analyses, help with budgets, biosketches, letters of support, manuscript review.

Early Career Investigators automatically qualify for 10 free hours of analysis.

Check out his...

Read more about Bioinformatics Support is available through the HU CFAR

The BSL-3 laboratory’s expanded capabilities to support virology work was provided through a generous gift from Mark and Lisa Schwartz, long-time supporters of the Ragon Institute. Through this gift, the BSL-3 was able to undergo upgrades that allow researchers throughout the Institute and across CFAR to safely research viral pathogens that affect the lives of millions of people across the globe.

Registration is open for the virtual IeDEA 2021 Global Meeting taking place April 7-9.

Each day will focus on different topics:

April 7, 8am-1215pm EDT: IeDEA early-stage investigator symposium

April 8, 8am-1215pm...

Read more about Register Now: IeDEA 2021 Global Meeting April 7-9 (International epidemiology Database to Evaluate AIDS)

As you may be aware, the Cross-Network TB Vaccine Working Group (TB Vaccine WG) Leadership are in the process of planning a multiday virtual meeting to develop a TB vaccine roadmap research for people living with HIV (PLWHIV), which will outline the current TB vaccine landscape and determine where TB vaccine research is headed. The meeting will be held in partnership with NIH/DAIDS. Attendees will include representatives from various organizations including members of the Cross-Network TB Vaccine Working Group, representatives from the WHO, stringent and local regulators (FDA, EMA...

Read more about Save the Date: Developing a TB Vaccine Roadmap: A Multi-Day Virtual Meeting Jan 22, 2021 - Feb 24, 2021

The HU CFAR is well aware that Dr. Galit Alter is an unprecedented collaborator and now everyone knows.

Boston Globe articles: https://www.bostonglobe.com/2020/12/10/magazine/2020-bostonians-year/

... Read more about 2020 Bostonian of the Year: Dr. Galit Alter

"Government service was never part of my plans. But every doctor knows that when a patient is coding, your plans don’t matter. You run to the code. And when a nation is coding—if you are called to serve, you serve." .... Rochelle Walensky

MGH's Rochelle Walensky to run CDC
https://news.harvard.edu/gazette/story/2020/12/mass-general-hospitals-rochelle-walensky-to-run-cdc/

Who is Rochelle Walensky:
https://www.npr.org/2020/12/09/944739752/who-is-rochelle-walensky-bidens-pick-for-cdc-director

Unafraid to speak her mind:
https://www.washingtonpost....

Read more about Dr. Walenksy will lead CDC

Congratulations to the Harvard investigators and teams that have recieved NIH funding for the following trials units and networks:

Read about the NIH structuring of Clinical Trials Networks:
...

Read more about Congrats: Refunded Harvard Investigators HIV CTU and Network Awards

The Harvard University Center for AIDS Research (HU CFAR) announced recently that Rajesh Gandhi and Galit Alter have taken on the positions of co-directors, with Gandhi assuming the additional title of principal investigator.

Gandhi and Alter are succeeding Bruce Walker, Harvard professor and director of the Ragon Institute of Massachusetts General Hospital (MGH), MIT, and Harvard. Walker served as director for more than 25 years and his leadership shaped the CFAR into the successful Center it is today.

Full article in the Gazette: ...

Read more about In the Gazette: Harvard University CFAR announces leadership change

AIDS Application Due Dates:  March 17, 2021; March 17, 2022; March 17, 2023

See full details: Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed)

Purpose: to support innovative, collaborative, interdisciplinary early-stage research to inform the development of innovative rapid, sensitive, simple, and cost-effective...

Read more about PAR-21-070: Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed)